Drug intelligence / Profile preview

WTYX10004

Development stage: Preclinical
Lead developer: Xiamen Innovax Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

WTYX10004 is a preclinical-stage vaccine candidate being developed by Xiamen Innovax Biotech (a subsidiary of Beijing Wantai Biological Pharmacy) and Sino-Innovax Biotech for the prevention of seasonal influenza. The vaccine is designed to protect against seasonal influenza virus infections. It is part of the company's pipeline of human vaccines targeting infectious diseases.

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on WTYX10004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WTYX10004.

Explore the full profile